Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
Celldex Therapeutics, Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. The company is engaged in the development and commercialization of immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases.
IPO Date: March 26, 1990
Sector: Healthcare
Industry: Biotech
Market Cap: $1.39B
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.43 | 3.07%
Avg Daily Range (30 D): $0.56 | 2.79%
Avg Daily Range (90 D): $0.60 | 3.06%
Institutional Daily Volume
Avg Daily Volume: 1.1M
Avg Daily Volume (30 D): .86M
Avg Daily Volume (90 D): .69M
Trade Size
Avg Trade Size (Sh.): 163
Avg Trade Size (Sh.) (30 D): 68
Avg Trade Size (Sh.) (90 D): 64
Institutional Trades
Total Inst.Trades: 4,382
Avg Inst. Trade: $2.08M
Avg Inst. Trade (30 D): $3.01M
Avg Inst. Trade (90 D): $2.46M
Avg Inst. Trade Volume: .05M
Avg Inst. Trades (Per Day): 2
Market Closing Trades
Avg Closing Trade: $2.85M
Avg Closing Trade (30 D): $2.44M
Avg Closing Trade (90 D): $2.54M
Avg Closing Volume: 74.35K
   
News
Jun 14, 2025 @ 2:48 PM
Celldex Presents Data Demonstrating Profound Long ...
Source: N/A
Mar 3, 2025 @ 1:01 PM
Celldex Therapeutics Presents Positive Preclinical...
Source: N/A
Mar 1, 2025 @ 5:45 PM
Celldex Therapeutics Presents Positive Results fro...
Source: N/A
Feb 20, 2025 @ 6:00 PM
Chronic Spontaneous Urticaria Market to Register I...
Source: Delveinsight
Dec 19, 2024 @ 1:01 PM
Celldex Initiates Phase 2 Study of Barzolvolimab i...
Source: N/A
Financials
  TTM Q4 2024 FY 2024
Basic EPS $-.81 $-.71 $-2.45
Diluted EPS $-.81 $-.71 $-2.45
Revenue $ .7M $ 1.18M $ 7.02M
Gross Profit $ $ $ 6.82M
Net Income / Loss $ -53.8M $ -47.09M $ -157.86M
Operating Income / Loss $ -62.74M $ -56.03M $ -195.08M
Cost of Revenue $ $ $ .2M
Net Cash Flow $ -11.22M $ -8.04M $ -6.46M
PE Ratio    
Splits
Feb 11, 2019:   1:15
Mar 10, 2008:   1:12
Mar 07, 2008:   1:12